These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 35434533)

  • 41. Anti-Viral and Immunomodulatory Properties of Propolis: Chemical Diversity, Pharmacological Properties, Preclinical and Clinical Applications, and In Silico Potential against SARS-CoV-2.
    Yosri N; Abd El-Wahed AA; Ghonaim R; Khattab OM; Sabry A; Ibrahim MAA; Moustafa MF; Guo Z; Zou X; Algethami AFM; Masry SHD; AlAjmi MF; Afifi HS; Khalifa SAM; El-Seedi HR
    Foods; 2021 Jul; 10(8):. PubMed ID: 34441553
    [TBL] [Abstract][Full Text] [Related]  

  • 42. BioAider: An efficient tool for viral genome analysis and its application in tracing SARS-CoV-2 transmission.
    Zhou ZJ; Qiu Y; Pu Y; Huang X; Ge XY
    Sustain Cities Soc; 2020 Dec; 63():102466. PubMed ID: 32904401
    [TBL] [Abstract][Full Text] [Related]  

  • 43. In vitro screening of a FDA approved chemical library reveals potential inhibitors of SARS-CoV-2 replication.
    Touret F; Gilles M; Barral K; Nougairède A; van Helden J; Decroly E; de Lamballerie X; Coutard B
    Sci Rep; 2020 Aug; 10(1):13093. PubMed ID: 32753646
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Human coronavirus 229E nonstructural protein 13: characterization of duplex-unwinding, nucleoside triphosphatase, and RNA 5'-triphosphatase activities.
    Ivanov KA; Ziebuhr J
    J Virol; 2004 Jul; 78(14):7833-8. PubMed ID: 15220459
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Toward wide-spectrum antivirals against coronaviruses: Molecular characterization of SARS-CoV-2 NSP13 helicase inhibitors.
    Perez-Lemus GR; Menéndez CA; Alvarado W; Byléhn F; de Pablo JJ
    Sci Adv; 2022 Jan; 8(1):eabj4526. PubMed ID: 34995115
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Myricetin Inhibits SARS-CoV-2 Viral Replication by Targeting M
    Xiao T; Cui M; Zheng C; Wang M; Sun R; Gao D; Bao J; Ren S; Yang B; Lin J; Li X; Li D; Yang C; Zhou H
    Front Pharmacol; 2021; 12():669642. PubMed ID: 34220507
    [TBL] [Abstract][Full Text] [Related]  

  • 47. In silico studies of selected multi-drug targeting against 3CLpro and nsp12 RNA-dependent RNA-polymerase proteins of SARS-CoV-2 and SARS-CoV.
    Udofia IA; Gbayo KO; Oloba-Whenu OA; Ogunbayo TB; Isanbor C
    Netw Model Anal Health Inform Bioinform; 2021; 10(1):22. PubMed ID: 33786291
    [TBL] [Abstract][Full Text] [Related]  

  • 48. In silico identification of potential inhibitors of key SARS-CoV-2 3CL hydrolase (Mpro) via molecular docking, MMGBSA predictive binding energy calculations, and molecular dynamics simulation.
    Choudhary MI; Shaikh M; Tul-Wahab A; Ur-Rahman A
    PLoS One; 2020; 15(7):e0235030. PubMed ID: 32706783
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Structural basis for backtracking by the SARS-CoV-2 replication-transcription complex.
    Malone B; Chen J; Wang Q; Llewellyn E; Choi YJ; Olinares PDB; Cao X; Hernandez C; Eng ET; Chait BT; Shaw DE; Landick R; Darst SA; Campbell EA
    Proc Natl Acad Sci U S A; 2021 May; 118(19):. PubMed ID: 33883267
    [TBL] [Abstract][Full Text] [Related]  

  • 50. FDA-approved thiol-reacting drugs that potentially bind into the SARS-CoV-2 main protease, essential for viral replication.
    Lobo-Galo N; Terrazas-López M; Martínez-Martínez A; Díaz-Sánchez ÁG
    J Biomol Struct Dyn; 2021 Jun; 39(9):3419-3427. PubMed ID: 32364011
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Modelling the active SARS-CoV-2 helicase complex as a basis for structure-based inhibitor design.
    Berta D; Badaoui M; Martino SA; Buigues PJ; Pisliakov AV; Elghobashi-Meinhardt N; Wells G; Harris SA; Frezza E; Rosta E
    Chem Sci; 2021 Oct; 12(40):13492-13505. PubMed ID: 34777769
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Identifying SARS-CoV-2 antiviral compounds by screening for small molecule inhibitors of nsp12/7/8 RNA-dependent RNA polymerase.
    Bertolin AP; Weissmann F; Zeng J; Posse V; Milligan JC; Canal B; Ulferts R; Wu M; Drury LS; Howell M; Beale R; Diffley JFX
    Biochem J; 2021 Jul; 478(13):2425-2443. PubMed ID: 34198323
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Computational target-based drug repurposing of elbasvir, an antiviral drug predicted to bind multiple SARS-CoV-2 proteins.
    Balasubramaniam M; Shmookler Reis RJ
    ChemRxiv; 2020 Apr; ():. PubMed ID: 32511290
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Lessons learnt from broad-spectrum coronavirus antiviral drug discovery.
    Bolinger AA; Li J; Xie X; Li H; Zhou J
    Expert Opin Drug Discov; 2024 Sep; 19(9):1023-1041. PubMed ID: 39078037
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Variable Inhibition of DNA Unwinding Rates Catalyzed by the SARS-CoV-2 Helicase Nsp13 by Structurally Distinct Single DNA Lesions.
    Sales AH; Fu I; Durandin A; Ciervo S; Lupoli TJ; Shafirovich V; Broyde S; Geacintov NE
    Int J Mol Sci; 2024 Jul; 25(14):. PubMed ID: 39063172
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A Repurposed Drug Interferes with Nucleic Acid to Inhibit the Dual Activities of Coronavirus Nsp13.
    Soper N; Yardumian I; Chen E; Yang C; Ciervo S; Oom AL; Desvignes L; Mulligan MJ; Zhang Y; Lupoli TJ
    ACS Chem Biol; 2024 Jul; 19(7):1593-1603. PubMed ID: 38980755
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Identification of new benzofuran derivatives as STING agonists with broad-spectrum antiviral activity.
    Paulis A; Onali A; Vidalain PO; Lotteau V; Jaquemin C; Corona A; Distinto S; Delogu GL; Tramontano E
    Virus Res; 2024 Sep; 347():199432. PubMed ID: 38969014
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Generalized open-source workflows for atomistic molecular dynamics simulations of viral helicases.
    Raubenolt B; Blankenberg D
    Gigascience; 2024 Jan; 13():. PubMed ID: 38869150
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Therapeutic implications of quercetin and its derived-products in COVID-19 protection and prophylactic.
    Ho WY; Shen ZH; Chen Y; Chen TH; Lu X; Fu YS
    Heliyon; 2024 May; 10(9):e30080. PubMed ID: 38765079
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Drug repurposing screen to identify inhibitors of the RNA polymerase (nsp12) and helicase (nsp13) from SARS-CoV-2 replication and transcription complex.
    Kuzikov M; Reinshagen J; Wycisk K; Corona A; Esposito F; Malune P; Manelfi C; Iaconis D; Beccari A; Tramontano E; Nowotny M; Windshügel B; Gribbon P; Zaliani A
    Virus Res; 2024 May; 343():199356. PubMed ID: 38490582
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.